These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15470439)

  • 1. Electoral campaign delays resolution of biotech issues.
    Fox JL
    Nat Biotechnol; 2004 Oct; 22(10):1193. PubMed ID: 15470439
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech as Bush bows out.
    Lorenzo A
    Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives. GOP sets its sights on Food and Drug Administration.
    Barnett AA
    Faulkner Grays Med Health; 1995 Feb; 49(8):suppl 1-4. PubMed ID: 10139918
    [No Abstract]   [Full Text] [Related]  

  • 4. The U.S. medical device industry: entrepreneurs' future hinges on reforms at the Food and Drug Administration.
    Kimbell JJ
    Food Drug Law J; 1996; 51(2):339-43. PubMed ID: 11822328
    [No Abstract]   [Full Text] [Related]  

  • 5. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 6. US Presidential transition prompts biotech policy frenzy.
    Fox JL
    Nat Biotechnol; 2001 Mar; 19(3):183-4. PubMed ID: 11231515
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA scrutinizes human stem cell therapies.
    Fox JL
    Nat Biotechnol; 2008 Jun; 26(6):598-9. PubMed ID: 18536668
    [No Abstract]   [Full Text] [Related]  

  • 8. An industry imperiled by regulatory bottlenecks.
    Naughton G
    Nat Biotechnol; 2001 Aug; 19(8):709-10. PubMed ID: 11479550
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA: a dromedary tale.
    Nat Biotechnol; 1997 Jan; 15(1):1. PubMed ID: 9035089
    [No Abstract]   [Full Text] [Related]  

  • 10. Summer recess might squeeze FDA reform bill.
    Fox JL
    Nat Biotechnol; 1997 Aug; 15(8):715. PubMed ID: 9333520
    [No Abstract]   [Full Text] [Related]  

  • 11. Fake biotech drugs raise concerns.
    Fox JL
    Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
    [No Abstract]   [Full Text] [Related]  

  • 12. Number crunching.
    Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894180
    [No Abstract]   [Full Text] [Related]  

  • 13. The US biotechnology industry: an analysis of trends.
    Dibner MD
    Aust J Biotechnol; 1988 Sep; 2(2):129-32. PubMed ID: 2485326
    [No Abstract]   [Full Text] [Related]  

  • 14. In need of rehab.
    Nature; 2005 Oct; 437(7060):789-90. PubMed ID: 16208322
    [No Abstract]   [Full Text] [Related]  

  • 15. Left in the dust of the campaign trail.
    Nat Biotechnol; 2000 Nov; 18(11):1119. PubMed ID: 11062387
    [No Abstract]   [Full Text] [Related]  

  • 16. Frustrated by regulatory delays at FDA, biotech companies warm to user fees.
    Gershon D
    Nature; 1992 Aug; 358(6388):616. PubMed ID: 1495553
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech patenting slows in 2004.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1198. PubMed ID: 16211048
    [No Abstract]   [Full Text] [Related]  

  • 18. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech under Barack.
    Fox JL
    Nat Biotechnol; 2009 Mar; 27(3):237-44. PubMed ID: 19270669
    [No Abstract]   [Full Text] [Related]  

  • 20. Insights into US public biotech sector using patenting trends.
    Aggarwal S; Gupta V; Bagchi-Sen S
    Nat Biotechnol; 2006 Jun; 24(6):643-51. PubMed ID: 16763590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.